Albert David Ltd. (BSE: 524075) is a Kolkata, West Bengal-based company in the Pharmaceuticals industry. With a market capitalisation of ₹476 Cr, it ranks #2,025 by market cap among the 6,137 Indian listed companies on FinBizNet, and #28 of 63 in Pharmaceuticals. At ₹763.70 (as of 25 Oct 2026), the share price is 18.0% below its 52-week high of ₹931.85 and 31.7% above its 52-week low of ₹579.90. The share price is down 4.7% over one year and up 9.4% over three months.
| Current Price | ₹763.70 |
|---|---|
| Market Cap | ₹476 Cr |
| BSE Code | 524075 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | -309.3 |
| Return on Equity | -0.38% |
| Return on Assets | -0.49% |
| 52-Week Range | ₹579.90 – ₹931.85 |
| 1-Year Price Change | -4.7% |
| 3-Month Price Change | +9.4% |
| Beta (1Y) | 0.66 |
| Dividend Yield | 0.62% |
| Headquarters | Kolkata, West Bengal |
| Website | www.albertdavidindia.com |
| Revenue | ₹101 Cr |
|---|---|
| Net Profit | ₹32 Cr |
| Net Margin | 31.6% |
| EPS (Basic) | ₹56.07 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India and internationally. It offers formulations for parenterals, oral/enterals, topical agents, aerosol, gynecology therapy, orthopedic, and vision care products. Albert David Limited was incorporated in 1938 and is headquartered in Kolkata, India.
1. Pharmaceuticals-This segment manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs.
1. Manufacturing of Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Albert David Ltd. | ₹476 Cr | -309.3 | -0.38% | ₹101 Cr | -4.7% |
Listed by market capitalisation. Ratios are shown for context only.
Albert David Ltd. is trading at ₹763.70, with a market capitalisation of ₹476 Cr.
Albert David Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Albert David Ltd. has a P/E of -309.3 and a return on equity of -0.38%.
Albert David Ltd. is listed on the BSE under the scrip code 524075.
Albert David Ltd.'s share price is down 4.7% over one year and up 9.4% over three months. Its 52-week range is ₹579.90 to ₹931.85.
In Q1 FY27, Albert David Ltd. reported revenue of ₹101 Cr and net profit of ₹32 Cr, with basic EPS of ₹56.07 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.